ALNYLAM PHARMACEUTICALS, INC. (ALNY) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 1 fund adding, and 1 fund trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($543.1K bought vs $398.9K sold). 0 members of Congress reported 0 purchases vs 1 sale. Latest close $149.40 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.
Deep Track Capital · Paradigm Biocapital Advisors · Dodge & Cox Funds — 5 tracked funds hold ALNY. See all holders.
Insiders bought on the open market (2 purchases, $543.1K) vs 1 sale ($398.9K). Latest buy: Nov 10, 2026. Insider trading 0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading
MBX BIOSCIENCES INC (MBX) · GENMAB A/S (GMAB) · TARSUS PHARMACEUTICALS INC (TARS) · VERA THERAPEUTICS INC (VERA) · BELITE BIO, INC (BLTE) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Deep Track Capital | 3.61% | 825,000 | NEW Q3 filed Nov 16 |
| Paradigm Biocapital Advisors | 2.71% | 480,000 | NEW Q3 filed Nov 16 |
| Dodge & Cox Funds | 0.31% | 1,955,393 | ADDED (+1.4%) Q3 filed Nov 13 |
| Deerfield Management | 0.21% | 67,935 | HELD Q3 filed Nov 16 |
| OrbiMed Advisors | 0.09% | 17,000 | TRIMMED (-85.7%) Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -48.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 788 of 8,857 filers |
| Long-only filers among them | 783 |
| Change vs 2026 Q1 | +12 net · 711 entered · 699 exited |
| Shares reported, all filers | 132,604,323 |
| Reported value, all filers | $38.3B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $3.7B |
| Net income · FY2025 | $313.7M |
| Total assets · FY2025 | $5.0B |
| Shares outstanding | 133,937,576 |
| Market cap (at latest close) | $20.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 23, 2026.
| Shares short · Oct 15, 2026 | 6,568,786 |
| Share of shares outstanding | 4.90% |
| Days to cover | 5.10 |
Shares short at recent settlements — Jul 31, 2026: 4.8M · Aug 14, 2026: 4.8M · Aug 31, 2026: 6.3M · Sep 15, 2026: 7.2M · Sep 30, 2026: 7.7M · Oct 15, 2026: 6.6M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 23, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 65 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 159 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 23, 2026.
2 insiders bought on the open market in the last 90 days (2 purchases, $543.1K), against 1 sale by 1 insider ($398.9K). Latest buy: Nov 10, 2026.
Source: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| Sigal Charles Elliott · 1,600 shares on Nov 10, 2026 · filed Nov 12, 2026 | $152.25 | -5.2% (close Nov 13, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Nov 13, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Sigal Charles Elliott | Buy | 1,600 | $152.25 | $243.6K | SEC filing | |
| Nov 9, 2026 | SCHULMAN AMY W | Buy | 1,910 | $156.82 | $299.5K | SEC filing | |
| Oct 2, 2026 | SUPRAN BRYAN | EVP, CLO and Secretary | Sell | 1,758 | $226.88 | $398.9K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | SUPRAN BRYAN | Officer | 1,758 | $398.9K | Oct 2, 2026 | SEC filing |
| Jun 1, 2026 | PYOTT DAVID E I | Director | 3,830 | $1.1M | Jun 1, 2026 | SEC filing |
| Apr 6, 2026 | McLaughlin Melissa | Officer | 2,286 | $731.7K | Apr 6, 2026 | SEC filing |
| Mar 5, 2026 | Fitzgerald Kevin Joseph | Officer | 658 | $213.0K | Mar 5, 2026 | SEC filing |
| Mar 5, 2026 | Garg Pushkal | Officer | 2,404 | $778.2K | Mar 5, 2026 | SEC filing |
| Mar 3, 2026 | Fitzgerald Kevin Joseph | Officer | 1,652 | $530.9K | Mar 3, 2026 | SEC filing |
| Mar 3, 2026 | Garg Pushkal | Officer | 1,775 | $570.4K | Mar 3, 2026 | SEC filing |
| Feb 27, 2026 | Garg Pushkal | Officer | 4,627 | $1.5M | Feb 27, 2026 | SEC filing |
| Feb 17, 2026 | Fitzgerald Kevin Joseph | Officer | 2,041 | $677.5K | Feb 17, 2026 | SEC filing |
| Jan 13, 2026 | Fitzgerald Kevin Joseph | Officer | 2,290 | $845.2K | Jan 13, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | Capital World Investors | SC 13G/A | 10,916,799 | 8.2% | Mar 31, 2026 | SEC filing |
| May 14, 2026 | Capital Research Global Investors | SC 13G/A | 9,471,181 | 7.1% | Mar 31, 2026 | SEC filing |
| May 6, 2026 | FMR LLC | SC 13G/A | 14,640,524.87 | 11.0% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 7,104,536 | 5.3% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Nov 5, 2025 | FMR LLC | SC 13G/A | 16,834,094.74 | 12.8% | Sep 30, 2025 | SEC filing |
| Apr 7, 2025 | The Vanguard Group | SC 13G/A | 13,056,605 | 10.0% | Mar 31, 2025 | SEC filing |
| Feb 13, 2025 | Capital Research Global Investors | SC 13G | 6,968,513 | 5.4% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
0 members of Congress reported buying (0 purchases vs 1 sale).
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Booker, Cory | Senate | D | 0 | 1 | Aug 11, 2026 | $1,001 - 15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 243 Lobbying Disclosure Act filings named this company as client, 2004–2026; most common issues: Medicare/Medicaid (158), Health Issues (71), Copyright/Patent/Trademark (30).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Insiders
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Financial Screens
· Growth — Revenue up every year for 5 straight years
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Growth — Latest revenue: $3.7B · 5-yr revenue CAGR: 49.8% · Straight growth years: 7
· Insider Net Buying — Buy txns: 2 · Sell txns: 1 · Buy value: $543.1K · Latest buy: Nov 10, 2026
· Distress Risk (Altman Z″) — Z″-Score: -0.11 · Working capital / assets: 0.52 · Retained earnings / assets: -1.35 · EBIT / assets: 0.10 · Equity / liabilities: 0.19
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2024 Q1, ranked #47 of 50.
Also held by the tracked funds that hold ALNY — ranked by lift, the co-holding pattern described in Methodology: MBX BIOSCIENCES INC (MBX) · GENMAB A/S (GMAB) · TARSUS PHARMACEUTICALS INC (TARS) · VERA THERAPEUTICS INC (VERA) · BELITE BIO, INC (BLTE) · COGENT BIOSCIENCES INC (COGT) · TYRA BIOSCIENCES INC (TYRA) · STRUCTURE THERAPEUTICS INC (GPCR).
| Filed | Items | Source |
|---|---|---|
| Nov 5, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events | SEC filing |
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jul 30, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
MBX BIOSCIENCES INC (MBX) · Track Record: how the signals scored · Practice timing on ALNY
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.